Paratus Sciences

Executive Summary

Paratus Sciences is a preclinical-stage biotechnology company founded in 2021 that exploits the unique evolutionary adaptations of bats to discover novel therapeutics for human diseases. By integrating genomics and informatics, its proprietary platform analyzes bat biology to identify promising targets for immunological, inflammatory, and cardiometabolic conditions with high unmet need. The company's approach is differentiated by focusing on naturally evolved mechanisms in bats that confer resistance to viruses and metabolic stress, potentially unlocking new drug classes. Despite being early-stage with no disclosed financing or pipeline details, Paratus Sciences represents a high-risk, high-reward opportunity in the biotech space, pending validation of its discovery engine and advancement of lead programs.

Upcoming Catalysts (preview)

• Q1 2027Lead Program Nomination and Preclinical Proof-of-Concept35% success
• Q4 2026Publication of Platform Validation Data in Peer-Reviewed Journal50% success
• Q2 2027Series A Financing Round to Fund Pipeline Development40% success